Biotinylated Human CA125/MUC16 Protein

产品信息(Product Info)

Recombinant Biotinylated Human CA125/MUC16 Protein is expressed from Expi293 with His tag and Avi tag at the C-terminal. It contains Gly12660-Met12923.[Accession | Q8WXI7]

分子量大小(Molecular Weight)

The protein has a predicted MW of 31.3 kDa. Due to glycosylation, the protein migrates to 52-80 kDa based on Tris-Bis PAGE result.


Less than 1EU per μg by the LAL method.


> 95% as determined by Tris-Bis PAGE


Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 5% trehalose is added as protectant before lyophilization.


Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/ml is recommended (usually we use 1mg/ml solution for lyophilization). Dissolve the lyophilized protein in distilled water.


-20 to -80°C for 12 months as supplied from date of receipt.
-20 to -80°C for 3-6 months in unopened state after reconstitution.
2-8°C for 2-7 days after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please avoid freeze-thaw cycles.

产品数据(Assay Data)
Tris-Bis PAGE

Biotinylated Human CA125 on Tris-Bis PAGE under reduced conditions. The purity is greater than 95%.


Immobilized Human MSLN, hFc Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human CA125, His Tag with the EC50 of 0.35μg/ml determined by ELISA.


MUC16, also known as the CA125 antigen, is a mucin protein that may be found in type I transmembrane or secreted forms that are used monitor the progress of epithelial ovarian cancer therapy.Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces.Binding to MSLN mediates heterotypic cell adhesion. This may contribute to the metastasis of ovarian cancer to the peritoneum by initiating cell attachment to the mesothelial epithelium via binding to MSLN.


CA125; CA-125; CA125MUC-16; FLJ14303; MUC16


(1)Das S , Batra S K. Understanding the Unique Attributes of MUC16 (CA125): Potential Implications in Targeted Therapy[J]. Cancer Research, 2015:0008-5472.CAN-15-1050.

(2)Rao T D , Park K J , Smith-Jones P , et al. Novel Monoclonal Antibodies Against the Proximal (Carboxy-Terminal) Portions of MUC16[J]. Applied immunohistochemistry & molecular morphology: AIMM / official publication of the Society for Applied Immunohistochemistry, 2010, 18(5):462-472.